945 reports of this reaction
3.3% of all CENEGERMIN BKBJ reports
#6 most reported adverse reaction
VISION BLURRED is the #6 most commonly reported adverse reaction for CENEGERMIN BKBJ, manufactured by Domp farmaceutici S.p.A.. There are 945 FDA adverse event reports linking CENEGERMIN BKBJ to VISION BLURRED. This represents approximately 3.3% of all 28,659 adverse event reports for this drug.
Patients taking CENEGERMIN BKBJ who experience vision blurred should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VISION BLURRED is moderately reported among CENEGERMIN BKBJ users, representing a notable but not dominant share of adverse events.
In addition to vision blurred, the following adverse reactions have been reported for CENEGERMIN BKBJ:
The following drugs have also been linked to vision blurred in FDA adverse event reports:
VISION BLURRED has been reported as an adverse event in 945 FDA reports for CENEGERMIN BKBJ. This does not prove causation, but indicates an association observed in post-market surveillance data.
VISION BLURRED accounts for approximately 3.3% of all adverse event reports for CENEGERMIN BKBJ, making it a notable side effect.
If you experience vision blurred while taking CENEGERMIN BKBJ, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.